余睿女士自 2023 年 12 月起担任本公司董事，并自 2024 年 6 月起兼任首席财务官。此外，余睿女士自 2021 年 5 月起担任海松资本医疗保健业务合伙人，负责制定医疗保健领域的整体投资策略。在此之前，余睿女士曾于 2014 年至 2021 年任职于华兴资本（China Renaissance），先后担任 CR Life Star Fund 合伙人及华兴资本医疗与生命科技组董事总经理。在此期间，她主导了近 30 个知名公司的私募融资和股权投资项目，其中多个项目成功上市，总交易额超过 30 亿美元。此前，她还曾在美国格理集团担任副总裁、研究部负责人兼中国医疗保健业务负责人，积累了深厚的行业资源。

余睿女士在美国工作十余年，拥有多元化的职业背景。她曾担任德意志银行（Deutsche Bank）等知名投行的美国医疗行业股票分析师，专注于美国生命科技公司的股票研究，并曾在全球顶尖药企 —— 美国基因泰克公司（Genentech）研发部任职五年，担任医药研究员。

余睿女士依次拥有芝加哥大学布斯商学院 MBA 学位、密苏里大学药理学硕士学位及广东药科大学药学学士学位。

Director and Chief Financial Officer

Ms. Rachel Yu has served as our director since December 2023 and Chief Financial Officer since June 2024. Ms. Yu is a partner at Oceanpine Capital’s healthcare practice since May 2021, where she is responsible for formulating the overall investment strategies in the healthcare sector and taking day-to-day principal leadership responsibility in financial and operational management of financial team, investment team and portfolio companies. 

Prior to that, she was a partner at China Renaissance Group, where she worked from 2014 to 2021 and took the principal responsibility in deal sourcing, and conducting due diligence on investment targets, including financial and operational data, financial models and valuation and compliance. From 2012 to 2014, Ms. Yu served as vice president/head of China healthcare research at Gerson Lehman Group. Prior to that, Ms. Yu worked as an equity analyst at Maxim Group, Rodman & Renshaw, and Deutsche Bank Securities. 

Ms. Yu received her MBA from the University of Chicago Booth School of Business (2008-2010), her MSc in Pharmacology from The University of Missouri School of Medicine (2000-2002), and her BSc in Pharmacy from Guangdong Pharmaceutical University (1995-1999).